Posted by Michael Wonder on 27 Sep 2023
ABM Therapeutics' ABM-1310 granted fast track designation by the FDA following orphan drug designation
26 September 2023 - ABM Therapeutics is pleased to announce today that the US FDA has granted fast track designation for the investigation of ABM-1310 for the treatment of glioblastoma patients carrying BRAF V600E mutation, following the orphan drug designation for ABM-1310 to treat malignant gliomas including GBM received in July.
ABM-1310 is an investigational therapeutic candidate currently undergoing clinical development for BRAF V600E mutant solid tumours.
